Chandraiah Godugu1,2, Ravi Doddapaneni1, Apurva R Patel1, Rakesh Singh3, Roger Mercer3, Mandip Singh4. 1. College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida, USA. 2. Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research, (NIPER), Hyderabad, Telangana, India. 3. Translational Science Laboratory, Florida State University, College of Medicine, Tallahassee, Florida, 32306, USA. 4. College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida, USA. mandip.sachdeva@famu.edu.
Abstract
PURPOSE: Oral administration of anticancer agents presents a series of advantages for patients. However, most of the anticancer drugs have poor water solubility leading to low bioavailability. METHODS: Controlled released spray dried matrix system of Gefitinib with hydroxypropyl β-cyclodextrin, chitosan, hydroxy propyl methyl cellulose, vitamin E TPGS, succinic acid were used for the design of formulations to improve the oral absorption of Gefitinib. Spray drying with a customized spray gun which allows simultaneous/pulsatile flow of two different liquid systems through single nozzle was used to prepare Gefitinib spray dried formulations (Gef-SD). Formulation was characterized by in vitro drug release and Caco-2 permeability studies. Pharmacokinetic studies were performed in Sprague Dawley rats. Efficacy of Gef-SD was carried out in A431 xenografts models in nude mice. RESULTS: In Gef-SD group 9.14-fold increase in the AUC was observed compared to free Gef. Improved pharmacokinetic profile of Gef-SD translated into increase (1.75 fold compared to Gef free drug) in anticancer effects. Animal survival was significantly increased in Gef formulation treated groups, with superior reduction in the tumor size (1.48-fold) and volumes (1.75-fold) and also increase in the anticancer effects (TUNEL positive apoptotic cells) was observed in Gef-SD treated groups. Further, western blot, immunohistochemical and proteomics analysis demonstrated the increased pharmacodynamic effects of Gef-SD formulations in A431 xenograft tumor models. CONCLUSION: Our studies suggested that Gefitinib can be successfully incorporated into control release microparticles based oral formulation with enhanced pharmacokinetic and pharmacodynamic activity. This study demonstrates the novel application of Gef in A431 tumor models.
PURPOSE: Oral administration of anticancer agents presents a series of advantages for patients. However, most of the anticancer drugs have poor water solubility leading to low bioavailability. METHODS: Controlled released spray dried matrix system of Gefitinib with hydroxypropyl β-cyclodextrin, chitosan, hydroxy propyl methyl cellulose, vitamin E TPGS, succinic acid were used for the design of formulations to improve the oral absorption of Gefitinib. Spray drying with a customized spray gun which allows simultaneous/pulsatile flow of two different liquid systems through single nozzle was used to prepare Gefitinib spray dried formulations (Gef-SD). Formulation was characterized by in vitro drug release and Caco-2 permeability studies. Pharmacokinetic studies were performed in Sprague Dawley rats. Efficacy of Gef-SD was carried out in A431 xenografts models in nude mice. RESULTS: In Gef-SD group 9.14-fold increase in the AUC was observed compared to free Gef. Improved pharmacokinetic profile of Gef-SD translated into increase (1.75 fold compared to Gef free drug) in anticancer effects. Animal survival was significantly increased in Gef formulation treated groups, with superior reduction in the tumor size (1.48-fold) and volumes (1.75-fold) and also increase in the anticancer effects (TUNEL positive apoptotic cells) was observed in Gef-SD treated groups. Further, western blot, immunohistochemical and proteomics analysis demonstrated the increased pharmacodynamic effects of Gef-SD formulations in A431 xenograft tumor models. CONCLUSION: Our studies suggested that Gefitinib can be successfully incorporated into control release microparticles based oral formulation with enhanced pharmacokinetic and pharmacodynamic activity. This study demonstrates the novel application of Gef in A431tumor models.
Authors: Anthony Gonçalves; Pascal Finetti; Renaud Sabatier; Marine Gilabert; José Adelaide; Jean-Paul Borg; Max Chaffanet; Patrice Viens; Daniel Birnbaum; François Bertucci Journal: Breast Cancer Res Treat Date: 2010-11-11 Impact factor: 4.872
Authors: Apurva R Patel; Mahavir B Chougule; Ed Lim; Kevin P Francis; Stephen Safe; Mandip Singh Journal: Nanomedicine Date: 2013-12-17 Impact factor: 5.307
Authors: Cedar H A Boakye; Ravi Doddapaneni; Punit P Shah; Apurva R Patel; Chandraiah Godugu; Stephen Safe; Santosh K Katiyar; Mandip Singh Journal: PLoS One Date: 2013-08-07 Impact factor: 3.240
Authors: Abdelrahman Y Sherif; Gamaleldin I Harisa; Fars K Alanazi; Fahd A Nasr; Ali S Alqahtani Journal: AAPS PharmSciTech Date: 2022-07-01 Impact factor: 4.026